Aldhaleei Wafa A, Kapoor Ekta, Shufelt Chrisandra, Wallace Michael B, Kling Juliana M, Cole Kristin, Winham Stacey J, Hedges Mary S, Faubion Stephanie S
From the Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, MN.
Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Jacksonville, FL.
Menopause. 2025 Feb 1;32(2):121-127. doi: 10.1097/GME.0000000000002460. Epub 2024 Dec 17.
Metabolic dysfunction-associated steatotic liver disease (MASLD) and vasomotor symptoms (VMS) are associated with increased cardiovascular disease risk. Although visceral adiposity has been linked to MASLD and VMS independently, this study aimed to evaluate associations between the two in midlife women.
A cross-sectional study of women aged 45-60 years receiving primary care at one of four sites was conducted from March 1 through June 30, 2021. MASLD diagnosis was obtained utilizing the International Classification of Diseases , Ninth Revision and Tenth Revision codes. VMS burden was evaluated with the Menopause Rating Scale and categorized as severe/very severe versus none/mild/moderate. Logistic regression models were used to assess the association between VMS and diagnosed MASLD both univariately and after individually adjusting for several risk factors.
A total of 4,599 women were included in the final analysis, 304 (7%) of whom had an MASLD diagnosis. On univariate analysis, women with an MASLD diagnosis were more likely to have severe/very severe VMS (odds ratio [OR], 1.50; 95% CI, 1.08-2.08; P = 0.015). However, the association between MASLD diagnosis and severe/very severe VMS was no longer statistically significant after individually adjusting for body mass index (adjusted OR, 1.36; 95% CI, 0.97-1.92) and hypertension (adjusted OR, 1.38; 95% CI, 0.99-1.93).
The relationship between MASLD and VMS appears to be best explained by other variables including BMI and hypertension. Although they do not appear to be directly linked, given the prevalence of bothersome VMS in midlife women, addressing VMS may enable greater adherence to lifestyle modifications as part of MASLD management.
代谢功能障碍相关脂肪性肝病（MASLD）和血管舒缩症状（VMS）与心血管疾病风险增加相关。虽然内脏肥胖已分别与MASLD和VMS相关联，但本研究旨在评估中年女性中两者之间的关联。
于2021年3月1日至6月30日对在四个地点之一接受初级保健的45至60岁女性进行了一项横断面研究。利用国际疾病分类第九版和第十版编码获得MASLD诊断。用更年期评定量表评估VMS负担，并分为重度/非常重度与无/轻度/中度。采用逻辑回归模型单因素分析以及在分别调整多个风险因素后评估VMS与确诊MASLD之间的关联。
最终分析共纳入4599名女性，其中304名（7%）被诊断为MASLD。单因素分析显示，诊断为MASLD的女性更有可能出现重度/非常重度VMS（比值比[OR]，1.50；95%置信区间[CI]，1.08 - 2.08；P = 0.015）。然而，在分别调整体重指数（调整后OR，1.36；95% CI，0.97 - 1.92）和高血压（调整后OR，1.38；95% CI，0.99 - 1.93）后，MASLD诊断与重度/非常重度VMS之间的关联不再具有统计学意义。
MASLD与VMS之间的关系似乎最好由包括体重指数和高血压在内的其他变量来解释。虽然它们似乎没有直接联系，但鉴于中年女性中令人困扰的VMS的患病率，解决VMS问题可能有助于更好地坚持作为MASLD管理一部分的生活方式改变。
